Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis

@article{Josse2013DenosumabAN,
  title={Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis},
  author={R. Josse and Aliya Khan and Daniel Ngui and M. Shapiro},
  journal={Current Medical Research and Opinion},
  year={2013},
  volume={29},
  pages={205 - 216}
}
  • R. Josse, Aliya Khan, +1 author M. Shapiro
  • Published 2013
  • Medicine
  • Current Medical Research and Opinion
  • Abstract Background: According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone therapy. Denosumab is indicated for postmenopausal patients at high risk for fracture or others who have failed, or are intolerant to, other osteoporosis… CONTINUE READING
    35 Citations
    Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis
    • 12
    Pharmacologic management of osteoporosis.
    • 11
    Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice.
    • 21
    • PDF

    References

    SHOWING 1-10 OF 69 REFERENCES
    Denosumab for the Management of Postmenopausal Osteoporosis
    • 7
    Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
    • David L Kendler, C. Roux, +6 authors Henry G Bone
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2010
    • 346
    Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    • 357
    • PDF
    Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    • 153
    • PDF
    Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study
    • J. Brown, D. Dempster, +5 authors J. Zanchetta
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2011
    • 45
    Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
    • 154